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Common variable immunodeficiency (CVID) is a primary 
immunodeficiency, which is characterized by insufficiency in the synthesis 
of immunoglobulins due to the disruption of B cell differentiation. The 
term “variable” in its name describes the heterogeneous clinical picture 
(infections, chronic lung disease, autoimmune diseases, gastrointestinal 
disorders, and malignancy) in this disease. Although the risk of 
developing malignancy in children with primary immunodeficiency is 
reported to be 4%, this rate is 10.000 times higher than healthy subjects 
of similar age. Non-Hodgkin lymphoma (NHL) accounts for 60% of 
malignancy in primary immunodeficiency patients (1). In the cohorts, 
the incidence of cancer in CVID patients was 15-21%. The most common 
malignancy was reported to be NHL, followed by gastric, breast, bladder, 
and cervix tumors (2-4). Our case shows that Hodgkin lymphoma may 
rarely develop in CVID and is presented to raise awareness. 
Our 9-year-old patient had severe mental retardation and optic atrophy 
complications due to convulsion lasting 20 minutes on postnatal 35th 
day. He had used antiepileptic (carbamazepine) treatment that was 
started at the age of 5 months with the diagnosis of epilepsy for three 
years. Laboratory tests requested for frequent bronchitis (five per year), 
otitis (thirteen per year) and antibiotic use (each month) revealed 
hypogammaglobulinemia with immunoglobulin G (IgG): 365 mg/
dL, IgA: <26 mg/dL, and IgM: <18 mg/dL. Lymphocyte subsets were 
normal. Anti-Rubella IgG was 19 U/mL, and anti-HBs was 148 mIU/mL in 
response to previous vaccines. Isohemagglutinin antibody was negative, 
and anti-HAV IgG (11.3 U/mL) and anti-CMV IgG (1 U/mL) titers against 
previous infections were weak positive. Fine needle aspiration biopsy of 
3x4 cm lymphadenopathy (LAP) in the left cervical region, which was 
detected during intravenous immunoglobulin administration for the 
third time with the diagnosis of CVID, revealed abundant lymphoid cells, 
immunoblasts and Reed-Stenberg cells with distinct nuclei, some with 
single, some with more than one nucleus. Abdominal ultrasonography 
was normal. Neck ultrasonography showed a large number of 
pathological LAPs in the left jugular chain and supraclavicular region, 
with the largest being 32 mm in diameter in the left jugulodigastric 
region. Positron emission tomography/computed tomography revealed 
hypermetabolic LAPs in the left upper lower jugular and supraclavicular 
space in the left side of the neck (Figure 1 a,b), slightly increased uptake 
in the spleen parenchyma, and diffuse hypermetabolic appearance at 
the bone marrow, suggesting lymphoproliferative malignancy. Excisional 
biopsy specimens were positive for CD30/CD15, and Fascin staining 
(compatible with nodular sclerosis type), and the patient was diagnosed 
as Hodgkin lymphoma. EBV test by polymerase chain reaction was 
negative. (The patient’s consent was obtained for presentation).
Despite the risk of toxicity, routine chemotherapy provided survival in 
80% of patients with NHL. It has been proposed to reduce the dose of 
treatment, but survival in standard chemotherapy patients is reported 
to be better than in those receiving low-dose chemotherapy (1,5). In our 
case, Hodgkin lymphoma (stage 3A) was diagnosed five months after the 
diagnosis of CVID, and a reduced dose of ABVD (Adriamycin, Bleomycin, 
Vinblastin, Dacarbazine) was decided.
It should be known that the risk of malignancy is increased in CVID, and 
the physical examination should be performed in routine hospitalizations, 
and especially LAP should be considered. This will provide the patient 
with early diagnosis and treatment.
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Figure 1. a,b) In the positron emission tomography/computed tomography 
report of our patient, mild hypermetabolic lymphadenopathy with 
conglomerate is observed on the left side of the neck (jugulo-digastric and 
supraclavicular lymph nodes)
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